Genocea Biosciences Inc. buy melinda
Summary
This prediction ended on 30.01.18 with a price of €6.67. The prediction for Genocea Biosciences Inc. disappointed with a performance of -26.01%. melinda has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | 1.085% | -0.846% | 12.464% | 58.472% |
| iShares Nasdaq 100 | -1.665% | -3.306% | 1.502% | 84.473% |
| iShares Nikkei 225® | 3.863% | 6.308% | 22.272% | 56.185% |
| iShares S&P 500 | 0.111% | -1.337% | 1.101% | 58.320% |
Comments by melinda for this prediction
In the thread Genocea Biosciences Inc. diskutieren
Stopped prediction by melinda for Genocea Biosciences Inc.
Genocea Biosciences Inc.
11.04.22
11.04.23
12.04.23
Genocea Biosciences Inc.
08.02.21
08.02.22
11.05.21
Genocea Biosciences Inc.
29.09.17
30.01.18
30.01.18